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Purpose: With the easing of restriction measures, repeated community-based sampling for 
tracking new COVID-19 infections is anticipated for the next 6 to 12 months. A non- 
invasive, self-collected specimen like saliva will be useful for such public health surveil-
lance. Investigations on the use of saliva for SARS-CoV-2 RT-PCR have largely been among 
COVID-19 in-pa\tients and symptomatic ambulatory patients with limited work in 
a community-based screening setting. This study was carried out to address this paucity of 
data and reported discrepancies in diagnostic accuracy for saliva samples.
Patients and Methods: From 29th June to 14th July 2020, adults presenting for COVID- 
19 testing at a community-based screening facility in Dubai, United Arab Emirates were 
recruited. Clinical data, nasopharyngeal swab in universal transport media and drooling 
saliva in sterile containers were obtained. Reverse transcriptase PCR amplification of SARS- 
CoV-2 RdRp and N genes was used to detect the presence of the SARS-CoV-2 virus.
Results: Of the 401 participants, 35 (8.7%) had viral detection in at least one specimen type 
and the majority (n=20/35; 57.1%) were asymptomatic. Both swab and saliva were positive 
in 19 (54.2%) patients, while 7 (20.0%) patients had swab positive/saliva negative results. 
There were 9 (25.7%) patients with saliva positive/swab negative result and this included 5 
asymptomatic COVID-19 patients undergoing repeat screening. Using the swab as the 
reference gold standard, the sensitivity and specificity of saliva were 73.1% (95% CI 52.2–-
88.4%) and 97.6% (95% CI 95.5–98.9%) while the positive and negative predictive values 
were 67.9% (95% CI 51.5–80.8%) and 98.1% (95% CI 96.5–99.0%), respectively.
Conclusion: The findings suggest good diagnostic accuracy for saliva and feasibility of 
utilization of specimen without transport media for SARS-CoV-2 RT-PCR. Saliva represents 
a potential specimen of choice in community settings and population-based screening.
Keywords: SARS-CoV-2, nasopharyngeal swab, molecular test, population-based 
screening, saliva
Introduction
The impact of the ongoing COVID-19 pandemic on healthcare, social and economic 
structures across the world is unprecedented.1 With over 21 million laboratory-confirmed 
cases globally (as of 17th August 2020), widespread testing to rapidly identify SARS- 
CoV-2-infected individuals and ensure appropriate implementation of isolation measures 
and contact tracing has been a crucial element in the strategy to contain the pandemic. 
Nasopharyngeal swab (NPS) has been used as the gold standard respiratory specimen for 
SARS-CoV-2 reverse-transcriptase PCR (RT-PCR) tests. The collection of NPS is 
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invasive and requires close contact between healthcare work-
ers (HCWs) and patients. Therefore, to protect HCWs from the 
risk of viral transmission, the use of personal protective equip-
ment (PPE) is mandated during specimen collection and this 
poses an additional strain on the resources of already stretched 
healthcare systems. Furthermore, patients experience a degree 
of discomfort during collection of the NPS specimens making 
it less acceptable particularly in children or when serial sam-
pling is required.
As continued community screening is increasingly 
recognised as crucial for the rapid identification of 
new outbreak clusters, the need for a non-invasive spe-
cimen which can be self-collected by the patient without 
the need for supervision by trained personnel continues 
to be highlighted. In this respect, saliva represents an 
attractive choice of specimen especially as previous 
studies on the laboratory detection of respiratory 
viruses, including coronaviruses, in hospitalized patients 
have demonstrated a high concordance rate of over 90% 
in saliva and NPS specimens.2,3 Posterior oropharyngeal 
saliva which requires deep throat coughing has been 
shown to be sensitive in a cohort of hospitalized 
COVID-19 patients although the throat-clearing man-
oeuvre required is a limitation for the use of this 
approach for unsupervised self-collection.4 Neat saliva 
obtained by the drooling technique, which can be self- 
collected without supervision, has been reported to show 
greater sensitivity compared to NPS in hospitalized 
COVID-19 patients and at-risk HCW on COVID-19 
wards.5–8 With the easing of lockdown restriction mea-
sures, repeated community-based sampling for rapid 
tracking of new infections in the population is antici-
pated and a non-invasive diagnostic specimen such as 
saliva will be useful for public health surveillance. 
Studies investigating the use of saliva for SARS-CoV-2 
RT-PCR have largely been carried out among COVID- 
19 in-patients and symptomatic ambulatory patients with 
most of these studies being underpowered with small 
sample sizes. Furthermore, emerging data on the use of 
neat saliva samples for SARS-CoV-2 testing in the 
ambulatory setting have shown conflicting reports of 
diagnostic accuracy and the need for further adequately 
powered studies with larger sample sizes continues to be 
highlighted.9–11 Therefore, this study was carried out to 
assess the diagnostic accuracy of neat saliva sampling 
for SARS-CoV-2 screening in a community-based 
ambulatory setting compared to NPS.
Patients and Methods
Setting and Participants
This study has been reported according to the Standards 
for the Reporting of Diagnostic Accuracy Studies 
(STARD) guidelines 2015 (Supplementary Figure).12 The 
study was carried out from 29th June−14th July 2020 at 
the Al Khawaneej Health Center in Dubai, United Arab 
Emirates (UAE). This is a designated COVID-19 screen-
ing facility accessible to the general population. An aver-
age of 235 patients are screened daily at the center, 
including contacts of confirmed positive cases, those with 
presumptive symptoms with or without history of expo-
sure as well as individuals concerned about possible infec-
tion. All adult patients undergoing COVID-19 testing at 
the center were eligible and informed consent was 
obtained from all participants. Ethical approval for the 
study was obtained from the Dubai Health Authority 
Research and Ethics Committee (DSREC-06/2020_15) 
and the Emirates Institutional Review Board for COVID- 
19 Research (DOH/CVDC/2020/1105).
Sample Size
We estimated a conservative infection prevalence of 
~5.0% across our screening centers. Therefore, 
a minimum sample size of 400 participants (including 20 
positive cases) was required to achieve a minimum power 
of at least 80% in order to detect a sensitivity of 80%, 
based on a target significance level of at least 0.05.13 We 
would also be able to detect a specificity of 95% as the 
minimum sample size to detect a specificity of 95% was 
243 participants (including 12 positive cases).
Sample Collection
Paired swab and saliva samples were obtained from all 
participants. The swab specimens were obtained by trained 
healthcare personnel using the standard technique for NPS 
collection as per COVID-19 screening protocol already in 
place at the facility. Swabs were placed in the Greiner Bio- 
One universal transport system (Greiner Bio-One, 
Kremsmünster, Austria) for transport to the diagnostic 
laboratory. To ensure consistency in saliva collection, the 
healthcare personnel were trained in giving instructions to 
the patients for saliva collection and a unified script was 
used. Saliva was collected using sterile containers without 
transport medium and samples were obtained at least 
one hour after the patient last consumed food, fluid, or 
smoked tobacco. Patients were asked to pool saliva in their 
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mouth for 1–2 minutes and then gently spit 2–4 mL of 
saliva into the provided sterile container. Demographic 
data and clinical information including indication for 
screening, history of co-morbidities, COVID-19 symptoms 
and vital signs were recorded for all participants. Paired 
swab and saliva samples were stored at room temperature 
and transferred to the diagnostic laboratory within three 
hours of collection.
SARS-CoV-2 Detection
Samples were processed for SARS-CoV-2 detection at 
Unilabs, Dubai, UAE which is a diagnostic laboratory 
approved for COVID-19 testing by the health authority 
and accredited by the EIAC accreditation body for 
COVID-19 testing under the ISO 15189:2012 standards. 
A record of the time of specimen collection and the time 
of arrival at the diagnostic laboratory was kept. All sam-
ples were processed immediately on arrival at the diag-
nostic laboratory. Viral RNA was extracted from 300 µL of 
each sample using the Chemagic viral RNA extraction kit 
on the automated Chemagic™ 360 Nucleic Acid Extractor 
(PerkinElmer, Baesweiler, Germany) according to the 
manufacturer’s instructions. Detection of SARS-CoV-2 
was carried out using the NeoPlex COVID-19 kit 
(GeneMatrix, Seoul, South Korea) for the RT-PCR ampli-
fication of the SARS-CoV-2 RdRp and N gene targets. The 
kit contains specific primers and dual-labelled probes for 
the amplification and simultaneous differentiation of 
SARS-CoV-2 and other beta-coronaviruses. The prepara-
tion of master mix and RT-PCR was carried out in accor-
dance with manufacturer-provided instructions. Briefly, the 
PCR master mix was prepared according to manufacturer- 
provided protocol to give a final volume per test of 
COVID-19 PPM 5 µL, One-step master mix 5 µL and 5 
µL DW (RNase-free water). The master mix was vortexed 
and 15 µL aliquots were placed into 0.2 mL PCR tubes 
followed by addition of 5 µL of extracted patient sample 
nucleic acid. The cycling protocol comprised of a first 
segment of one cycle of 50°C for 30 minutes followed 
by the second segment of a single cycle of 95°C for 15 
minutes. This was followed by 40 cycles of 95°C for 15 
seconds and 60°C for 60 seconds. Cycle threshold of ≤40 
was taken as cut off for positive result for both target 
genes. The results were interpreted in accordance with 
the UAE Federal guidelines (NCEMA UAE Expert Panel- 
May 2020) which are in line with manufacturer guidelines, 
and a “detected” result for SARS-CoV-2 was rendered if 
two gene targets or only the RdRp gene target was 
amplified and “non-detected” result if all gene targets 
were not amplified, while the manufacturer provided inter-
nal, negative and positive controls as well as third party 
negative and positive controls included in every run 
remained validated.
Statistical Analysis
Data were entered and analysed using SPSS statistical 
software version 24. Descriptive statistics for categorical 
variables are presented as number (percent) and for con-
tinuous variables as mean ±standard deviation (SD) or 
median (interquartile range; IQR). Comparison of means 
was carried out using Student’s t-test with statistical sig-
nificance at 0.05. The sensitivity, specificity, positive pre-
dictive value (PPV), negative predictive value (NPV) and 
a 95% confidence interval (CI) were calculated. Kappa 
coefficient was used to estimate agreement between swab 
and saliva RT-PCR test results.
Results
A total of 401 participants who provided both swab and 
saliva specimens were enrolled. The mean age (± SD) of 
participants was 35.5 ± 9.5 years and the majority were 
males (n/N=329/401; 82.0%). History of contact with con-
firmed COVID-19 patients was obtained in 176 (43.9%) 
participants and 48.6% (n=195) reported that they were 
asymptomatic. Majority of samples arrived in the labora-
tory within 2–3 hours of collection with median (IQR) of 2 
hours 48 minutes (1 hr 6 mins – 2 hrs 45 mins). The 
volume of saliva produced by the majority of patients 
was 2–3 mL and viral detection in both swab and saliva 
was recorded for three patients who had a saliva volume 
of 1 mL.
A total of 35 (8.7%) patients showed viral detection by 
SARS-CoV-2 RT-PCR from at least one specimen type and 
both the RdRp and N gene targets were detectable in all positive 
samples. The overall prevalence for COVID-19 diagnosis by 
swab RT-PCR was 6.5% (n/N=26/401) and 7.0% by saliva RT- 
PCR (n/N=28/401). Among the 35 patients that had a positive 
test by either specimen, 20 (57.1%) were asymptomatic and 
whilst 12 patients self-reported having fever, only four were 
febrile with temperature ≥37.5°C (mean ± SD 38.0 ± 0.3°C). 
Other self-reported symptoms were sore-throat (n=12), muscle 
pain (n=6) and two patients each reported shortness of breath, 
anosmia, and loss of taste. The median (IQR) onset of symp-
toms prior to the test was 2.5 (1–14) days. Table 1 shows the 
demographic and clinical characteristics of all patients who 
tested positive for SARS-CoV-2.
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Among the 35 patients with positive viral detection, both 
swab and saliva were positive in 19 (54.3%), while 7 (20.0%) 
had swab positive/saliva negative results. There were 9 
(25.7%) patients with saliva positive/swab negative result 
and five of these were confirmed asymptomatic COVID-19 
patients undergoing repeat screening. The mean (± SD) dura-
tion since the last test result in these 5 patients was 14 ± 7 days. 
Table 2 shows the distribution of SARS-CoV-2 detection in 
swab and saliva specimens. Using the swab as the reference 
gold standard, the sensitivity and specificity of saliva was 
73.1 % (95% CI 52.2–88.4%) and 97.6% (95% CI 95.5–-
98.9%), respectively. The PPV and NPV were 67.9% (95% 
CI 51.5–80.8%) and 98.1% (95% CI 96.5–99.0%), respec-
tively. The accuracy was 96.0% (95% CI 93.6–97.7%) and 
Kappa coefficient was 0.68 (95% CI 0.53–0.82).
Among the 19 patients with paired positive samples, 
the median cycle threshold (Ct) values for RdRp and 
N gene targets were 29.6 (IQR 24.8–35.0) and 28.9 (IQR 
24.5–35.0), respectively, in saliva; while the swab Ct 
values were RdRp 28.1 (IQR 22.6–31.8) and 28.0 (IQR 
23.1–32.3) N gene target (Figure 1 shows the Ct values for 
paired samples). RdRp and N gene median Ct of 36.1 (IQR 
33.9–37.1) and 36.3 (IQR 34.0–37.5), respectively, were 
found in saliva samples (n=9) which had a negative paired 
swab. Similarly, median RdRp and N gene Ct was 36.4 
(IQR 35.1–38.6) and 37.5 (IQR 32.5–38.2), respectively,  
Table 1 Profile of Patients with SARS-CoV-2 RT-PCR Positive Finding
SARS-CoV-2 RT-PCR Positive (N=35)
Swab+ Saliva Positive* 
(n=19)
Swab Only Positive* 
(n=7)
Saliva Only Positive* 
(n=9)
Age (years), mean ± SD** 30.6 ± 12.1 35 ± 8.6 32.1 ± 5.7
Male, n (%) 13 (68.4) 6 (85.7) 9 (100)
BMI, mean ± SD 24.9 ± 3.5 25.4 ± 4.2 26.6 ± 4.2
Smoker, n 2 Nil 1
Has co-morbidity,# n 1 2 2
Symptomatic at presentation, n (%) 11 (57.9) 3 (42.8) 6 (66.7)
Duration of symptoms prior to the test (days), median 
(IQR)
2 (2–4) 2 (0) 4 (2–9)
Reported symptoms at presentation, n (%)
Fever (self-reported) 11 (57.9) 1 (14.2) Nil
Cough 3 (15.7) 2 (28.5) 2 (22.2)
Sore throat 7 (36.8) 2 (28.5) 3 (33.3)
Shortness of breath 2 (10.5) Nil Nil
Muscle pain 6 (31.6) Nil Nil
Anosmia 2 (10.5) Nil Nil
Loss of taste Nil 2 (28.5) Nil
Vital signs
Body temperature (oC), mean ± SD 36.9 ± 0.5 36.9 ± 0.6 36.4 ± 0.3
Body temperature ≥37.5°C, n 3 1 Nil
Oxygen saturation, mean ± SD 99.0 ± 0.8 98.8 ± 0.8 99.2 ± 1.3
Risk factor
Close contact with confirmed COVID-19 patient, n 
(%)
11 (57.9) 7 (100.0) 6 (66.6)
Travel history, n (%) Nil Nil 1 (11.1)
Notes: *Based on SARS-CoV-2 RT-PCR positive; **Not statistically different across groups; #Hypertension and diabetes.
Table 2 Viral Detection in Saliva and Swab Specimens
SARS-CoV-2 RT-PCR (N=401) Swab
Detected Not Detected
Saliva Detected 19 9
Not detected 7 366
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for swab samples (n=7) which had paired negative saliva. 
Comparison of Ct values in patients with both saliva and 
swab positive samples versus those with either saliva or 
swab only positive showed significantly higher Ct values 
for both target genes in the latter (p<0.05; Figure 2).
Discussion
The findings from this study indicate that neat saliva has good 
diagnostic accuracy when compared to the gold standard NPS 
and it has the potential to be a specimen of choice in commu-
nity settings and population-based screening, especially for 
children. As communities re-open and restriction measures 
are eased, repeated sampling of individuals might become 
necessary for the rapid identification of new infection clusters. 
Hence, an understanding of the usefulness of saliva in 
a community-based screening setting is crucial. This study 
was carried out in the context of a busy community-based 
screening facility which caters to a population with diverse 
levels of risk potential and absent or mild symptoms. Our 
findings show that in such a setting, neat saliva is useful for 
SARS-CoV-2 RT-PCR, particularly in asymptomatic patients. 
These findings are in agreement with previous work investigat-
ing ambulatory patients in a busy screening clinic in 
Melbourne, Australia.11 Furthermore, we also demonstrate 
the feasibility of using saliva without the addition of transport 
media. During the ongoing pandemic, the cost of sample 
collection devices with transport media and challenges with 
supply logistics significantly impacted screening capability of 
healthcare systems particularly in resource-limited settings. 
The ability to use neat saliva will be crucial in addressing 
such challenges especially given the potential future scenario 
of repeated population screening. The timeframe from sample 
collection to arrival in the laboratory for processing we have 
shown in this study is envisaged to be feasible for high-volume 
community-based screening centers. In similar work by 
Williams et al,11 samples were transported to the laboratory 
(median time of three hours) without transport media with the 
addition of Amies media in the laboratory.
In previous comparative studies of upper and lower 
respiratory samples for SARS-CoV-2 RT-PCR, the sensi-
tivity for NPS specimen was 63–73% which is similar to 
our reported sensitivity for saliva.8,14,15 Although most of 
the indices for diagnostic accuracy in this study are 
aligned with those reported in similar studies in cohorts 
of hospitalized COVID-19 patients and symptomatic 
ambulatory individuals, our sensitivity and positive pre-
dictive values are on the lower end.5,7,9,10 This difference 
is probably due to clinical heterogeneity in patients 
(48.6% asymptomatic in our sample). As this study was 
carried out in a screening center, patients with severe 
COVID-19 did not form part of our study population. It 
has been shown that higher sensitivity is consistently 
seen in those with severe disease probably reflecting the 
higher viral load associated with COVID-19 severity.16 
Indeed, our finding that patients with lower Ct values 
(indicative of higher viral load) are more likely to have 
combined swab and saliva positive results is consistent 
with reported literature on the association between test 
sensitivity and high viral load. Diagnostic accuracy is 
Figure 1 SARS-CoV-2 RT-PCR cycle threshold (Ct) values for the target genes in 
patients with paired positive samples (i.e. both swab and saliva samples positive). 
Notes: (A) Ct values for RdRp gene in the swab and saliva of patients with paired 
positive samples. (B) Ct values for N gene in the swab and saliva of patients with 
paired positive samples.
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crucial for the use of saliva in the community setting 
wherein lower prevalence with a predominance of asymp-
tomatic and mildly symptomatic cases are expected. In 
light of these, it is interesting that our findings also 
demonstrate that half of the patients who were identified 
only by their saliva RT-PCR findings were confirmed 
COVID-19 patients undergoing retesting and they would 
have been missed based on their negative swab results. 
However, in keeping with previous literature, our data 
also indicate that neither saliva or swab specimen are 
100% sensitive for the detection of SARS-CoV-2 as we 
also had seven patients with swab positive/saliva negative 
results.7,8 Although the use of combined saliva and swab 
specimens for increased diagnostic accuracy has been 
suggested,7 in a scenario wherein repeated population 
sampling might be expected, our findings support the 
notion that saliva represents an alternative low-cost diag-
nostic specimen for SARS-CoV-2 screening particularly 
with the associated ease of collection and minimal risk 
for HCWs. A limitation of this study was that we only 
used one type of SARS-CoV-2 RT-PCR kit; hence, we 
suggest further investigations using kits for detection of 
other viral gene targets. As there are limited studies 
carried out in the context of community-based screening, 
we recommend additional studies for further evaluation 
of saliva for SARS-CoV-2 screening in these settings 
possibly including children and the elderly as well as 
multiple sampling for temporal profiling.
Figure 2 Comparison of RT-PCR cycle threshold (Ct) in paired positive swab and saliva versus samples with only one specimen type positive. 
Notes: (A) Ct values for RdRp and N genes in saliva: saliva positive/swab positive samples had significantly lower Ct values compared to saliva only positive samples. (B) Ct 
values for RdRp and N genes in swab: swab positive/saliva positive samples had significantly lower Ct values compared to swab only positive samples.
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Conclusion
The findings suggest good diagnostic accuracy for neat 
saliva and indicate the feasibility of utilization of saliva 
specimen without transport media for SARS-CoV-2 RT- 
PCR. Saliva represents a potential specimen of choice in 
community settings and population-based screening, espe-
cially as a non-invasive alternative for children and the 
elderly.
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